Expression of Tumor-Associated Surface Antigens and Their Correlation to Parameters of Malignancy in Human Malignant Melanoma

  • C. Sorg
  • J. Brüggen
  • V. Klimetzek
  • E. Macher
Conference paper


While there is wide agreement, that tumor cells express different sets of structural elements on their cell surface compared to their normal counterparts, the question is still unsettled, whether the different structures serve also as tumor specific antigens and are functional in an immunologic or nonimmunologic rejection mechanism. In recent studies (15) it, therefore, was investigated whether serologic reactions can be found in melanoma patients against cultured melanoma cells. A considerable proportion of positively reacting antisera was found not only in melanoma patients, but also in patients with tumors other than melanoma and healthy control persons. An analysis of the specificity revealed that besides some reactivity against blood group and histocompatibility antigens, the reactivity was mainly directed against tumor-associated fetal antigens. These fetal antigens, however, seemed not to be expressed uniformly and in a constant manner on all melanoma cell lines. While every cell line seemed to express its own individually grouped pattern of tumor-associated surface antigens, it was also found, that a given cell line was heterogeneous in terms of expressed antigens on the subpopulations of which the cell line is composed. In addition, single cell clones derived from the same cell line had been shown to vary considerably in respect to morphology and growth behavior (16).


Melanoma Cell Plasminogen Activator Melanoma Patient Melanoma Cell Line Fetal Tissue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    DEUTSCH, B.G., MERTZ, E.T.: Science 170, 109 (1970)CrossRefGoogle Scholar
  2. 2.
    FIDLER, I.J., KRIPKE, M.L.: Science 197, 893 (1977)PubMedCrossRefGoogle Scholar
  3. 3.
    FOGH, J., FOGH, H.: Ann. NJ. Acad, Sci. 172, 15 (1969)Google Scholar
  4. 4.
    FOGH, J., FOGH, J.M., QRFEO, T.: J. Natl. Cancer Inst. 59, 221 (1977)PubMedGoogle Scholar
  5. 5.
    HELMKAMP, R.W., GOODLAND, R.L., BALE, W.F., SPAR, I.L., MUTSCHLER, L.E.: Cancer Res. 20, 1495 (1960)PubMedGoogle Scholar
  6. 6.
    KILLION, J.J., KOLLMORGEN, D.N.: Nature (London) 259, 674 (1976)CrossRefGoogle Scholar
  7. 7.
    MACHER, E., MÜLLER, CH., SORG, G., GASSEN, A., SORG, C.: Behring Institut Mitt. 56, 86 (1975)Google Scholar
  8. 8.
    MÜLLER, CH., SORG, C.: Eur. J. Immunol. 5, 175 (1975)PubMedCrossRefGoogle Scholar
  9. 9.
    NISHIOKA, K., IRIE, R.S., KAWANA, T., TAKEUCHI, S.: Int. J. Cancer 4, 139 (1969)PubMedCrossRefGoogle Scholar
  10. 10.
    OSSOWSKI, L., UNKELESS, J.C., TOBIA, A., QUINGLEY, J.P., RIFKIN, D.B., REICH, E.: J. Exp. Med. 137, 112 (1973)PubMedCrossRefGoogle Scholar
  11. 11.
    OSSOWSKI, L., QUINGLEY, J.P., REICH, E.: J. Biol. Chem. 249, 4312 (1974)PubMedGoogle Scholar
  12. 12.
    QUIGLEY, J.P., OSSOWSKI, J.P., REICH, E.: J. Biol. Chem. 249, 4306 (1974)PubMedGoogle Scholar
  13. 13.
    RIFKIN, D.B., FOGH, J.M., ORFEO, T.: J. Natl. Cancer Inst. 139, 1317 (1974)Google Scholar
  14. 15.
    SEIBERT, E., SORG, C., HAPPLE, R., MACHER, E.: Int. J. Cancer 19, 172 (1977)PubMedCrossRefGoogle Scholar
  15. 16.
    SORG, C., BRÜGGEN, J., SEIBERT, E., MACHER, E.: Cancer Immunol. Immunother. 3, 259 (1978)CrossRefGoogle Scholar
  16. 17.
    UNKELESS, J.C., TOBIA, A., OSSOWSKI, L., QUINGLEY, J.P., RIFKIN, D.B., REICH, E.: J. Exp. Med. 137, 85 (1973)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1979

Authors and Affiliations

  • C. Sorg
    • 1
  • J. Brüggen
    • 1
  • V. Klimetzek
    • 1
  • E. Macher
    • 1
  1. 1.Universitäts-HautklinikAbteilung für Experimentelle DermatologieMünsterGermany

Personalised recommendations